ACE-Breast-03: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects Previously Treated with T-DXd
Condition: Breast Cancer
Sponsor: Ambrx, Inc.
Full Title
Protocol ACE-Breast-03: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Study Treatment
HER2 targeting antibody-drug conjugate ARX788
Eligibility/Info
HER2-positive metastatic breast cancer treated with up to 5 prior lines of therapy in the metastatic setting, one of which included trastuzumab deruxtecan.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
